Thymulin (Facteur Thymique Serique (FTS), Serum Thymic Factor)

Thymulin is one of the three classical thymic peptide hormones, alongside thymosin alpha-1 and thymopoietin. Discovered and characterized by J.F. Bach and colleagues in the 1970s and 1980s, it was originally called Facteur Thymique Serique (FTS, or Serum Thymic Factor) before being renamed thymulin after its structure was determined. What makes thymulin biochemically unique is its absolute requirement for zinc. The active form is a thymulin-zinc complex where a single zinc ion coordinates with the peptide's histidine and asparagine residues, stabilizing the biologically active conformation. Without zinc, thymulin adopts an inactive structure that can't bind its receptors. This zinc dependency has a direct clinical implication: zinc-deficient individuals have low functional thymulin levels even if their thymus is producing the peptide normally (PMID: 10378560). Thymulin levels decline dramatically with age as the thymus involutes. In humans, thymulin is readily detectable in children and young adults but drops to near-zero by age 60-70. This decline parallels the well-documented reduction in naive T-cell production and immune competence that characterizes immunosenescence. The therapeutic hypothesis is straightforward: if declining thymulin contributes to age-related immune dysfunction, then supplementing thymulin could partially restore immune competence. In animal models, this works. Thymulin administration to aged mice restores certain T-cell functions, improves vaccine responses, and reduces age-related inflammation. Reggiani et al. (PMID: 24557040) showed that intranasal thymulin had anti-inflammatory and neuroprotective effects in demyelination models, suggesting benefits beyond simple immune restoration. The gap between animal data and clinical application is significant for thymulin. Unlike thymosin alpha-1 (which has been used clinically in millions of patients worldwide), thymulin hasn't been through human clinical trials for therapeutic supplementation. The basic biology is solid, backed by hundreds of published papers, but the translation to human therapy is early-stage. Practical considerations limit access. Thymulin is not widely available from compounding pharmacies and is primarily sourced through research peptide suppliers. The peptide's instability (particularly the lability of the zinc-binding complex) creates formulation challenges. Anyone pursuing thymulin supplementation should ensure their zinc status is optimized, as the peptide is literally inactive without adequate zinc. For individuals interested in thymic peptide therapy with more clinical backing, thymosin alpha-1 has a much deeper clinical evidence base and wider availability. Thymulin remains an interesting research compound with strong mechanistic rationale but limited clinical validation for supplemental use.